ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO834

Curcumin: A Nutritional Strategy to Control Oxidative Stress in Patients Undergoing Peritoneal Dialysis

Session Information

Category: Health Maintenance‚ Nutrition‚ and Metabolism

  • 1400 Health Maintenance‚ Nutrition‚ and Metabolism

Authors

  • Mafra, Denise, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil
  • Reis, Drielly Cristhiny Mendes de Vargas, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil
  • Baptista, Beatriz Germer, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil
  • Cardozo, Ludmila Fmf, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil
  • Ribeiro-Alves, Marcelo, Fundacao Oswaldo Cruz, Rio de Janeiro, RJ, Brazil
  • de Paiva, Bruna Regis, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil
  • Alvarenga, Livia De almeida, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil
  • Fouque, Denis, Universite Claude Bernard Lyon 1, Villeurbanne, Auvergne-Rhône-Alpes , France
  • Leite, Maurilo, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
Background

Patients with chronic kidney disease (CKD) on peritoneal dialysis (PD) present a high production of reactive oxygen species (ROS) that lead to oxidative stress and inflammation. Bioactive compounds such as curcumin (from turmeric) have been tested as nutritional strategies to mitigate both complications. The aim of this study was to evaluate the effect of curcumin supplementation on lipid peroxidation and inflammatory markers in patients with CKD on PD.

Methods

In this longitudinal, randomized, single-blind, placebo-controlled trial, 42 patients were randomized into two groups: curcumin (1.5g/d with 98.42% of curcuminoids) or placebo for 3 months. The malondialdehyde (MDA) plasma levels (lipid peroxidation marker) and TNF-α and IL-6 were measured before and after the intervention.

Results

Twenty-four patients completed the study, 10 in the curcumin group (54 yr, 3 men) and 14 in the placebo group (52 yr, 5 men). MDA plasma levels were significantly reduced after three months of curcumin supplementation (Figure 1), whereas remained unchanged in the placebo group. The inflammation markers did not change after intervention in both groups.

Conclusion

Curcumin supplementation may be a good strategy to reduce oxidative stress in patients undergoing PD.

Funding

  • Government Support – Non-U.S.